Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S40-S45. doi: 10.1093/jpids/piac062.
Cystic fibrosis (CF) pulmonary exacerbations (PEx) are clinical events that commonly result in increased treatment burden, decreased quality of life, and accelerated lung disease progression. CF PEx have historically been approached as though dealing with acute infections, and antibiotic treatments have been associated with improved outcomes. In this review, we discuss data supporting a causal role of CF airway infection in PEx as well studies that highlight our knowledge gaps in regard to PEx definitions, pathophysiology, and optimal treatment approaches. In the era of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy, and the continually increasing health and longevity of persons with CF, a better understanding of PEx and further optimization of PEx antibiotic treatment approaches are needed.
囊性纤维化（CF）肺部加重（PEx）是常见的临床事件，通常会增加治疗负担、降低生活质量，并加速肺部疾病进展。CF PEx 传统上被视为处理急性感染的方法，抗生素治疗与改善预后相关。在这篇综述中，我们讨论了支持 CF 气道感染在 PEx 中起因果作用的证据，以及突出我们在 PEx 定义、病理生理学和最佳治疗方法方面知识空白的研究。在高效 CF 跨膜电导调节剂治疗的时代，以及 CF 患者健康和寿命的不断延长，我们需要更好地了解 PEx，并进一步优化 PEx 抗生素治疗方法。
